Analysts’ Viewpoint on Market Scenario
The global market for inotropic agents is expected to grow at a rapid pace in the near future due to various factors such as increase in the geriatric population, rise in the incidence of heart failure, and expansion in the healthcare sector. Technological advancements in drug development and delivery methods are also augmenting the inotropic agents market development.
However, industry growth is likely to be hindered by factors such as high cost of inotropic agents, limited product pipeline, and the availability of alternative treatments. Key players in the industry are investing in R&D to improve the efficacy and safety of inotropic agents and to develop new, more advanced products.
Inotropic agents are drugs that are used for the treatment of heart failure and other cardiac conditions. They alter the ionic concentration of the heart muscles, which in turn, affects the flow of calcium ions into the cells. This leads to an increase or decrease in the strength and rate of the heart's contractions, depending on the type of inotropic agent employed.
Heart failure is a condition in which the heart cannot pump enough blood to meet the body's demands, leading to fatigue, shortness of breath, and fluid accumulation in the legs and ankles. Inotropic agents improve the force of contraction of the heart muscle. Thus, surge in the prevalence of cardiovascular diseases is projected to spur the inotropic agents market growth in the near future. Rise in the geriatric population and increase in adoption of unhealthy lifestyles are also likely to boost the demand for inotropic agents in the near future.
Inotropic agents play a crucial role in the management of heart failure. Awareness about the importance of inotropic agents is growing among healthcare providers and patients in improving the symptoms and quality of life of patients with heart failure. This is estimated to propel the inotropic agents market size in the next few years. Additionally, government initiatives to increase awareness about heart failure, improve access to healthcare, and support research and development in the field are also contributing to the high demand for inotropic agents.
The positive inotropic agents type segment is projected to hold major share during the forecast period, as per the latest inotropic agents industry report. Positive inotropic agents help increase the strength of heart contractions. This makes them an effective treatment option for heart failure and other conditions that lead to weak heart muscles. Positive inotropic agents are the most commonly used type of inotropic agents and are prescribed to help improve the heart's ability to pump blood.
According to the latest inotropic agents market analysis, the heart failure and cardiogenic shock indication segment is estimated to dominate the industry from 2023 to 2031. Heart failure and cardiogenic shock are characterized by the inability of the heart to pump enough blood to meet the body's needs. Inotropic agents are employed to enhance the contractility of the heart muscle and increase blood flow, thereby improving the symptoms of heart failure and cardiogenic shock.
According to the latest inotropic agents market trends, the parenteral route of administration segment is expected to hold largest share during the forecast period. Inotropic agents are often administered via the parenteral route, as it allows for rapid and direct delivery of drugs to the heart. This is especially important in emergency situations, such as cardiogenic shock, where rapid treatment is critical. In these cases, the parenteral administration of inotropic agents can help restore blood flow to the body's vital organs and improve the heart's ability to pump blood.
North America is projected to dominate the industry from 2023 to 2031. High prevalence of heart failure and other cardiac conditions, rise in the geriatric population, and the presence of a large number of pharmaceutical companies and research institutions are boosting market expansion in the region. The U.S. is a major growth engine of the industry in North America.
The market in Asia Pacific is estimated to grow at a rapid pace during the forecast period. The healthcare sector is expanding rapidly in the region due to surge in government expenditure on the healthcare sector. China and India are major growth engines of the industry in Asia Pacific. Rise in demand for advanced healthcare technologies is also propelling market statistics in the region.
The global market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent inotropic agents market developments. Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, and Cipla Inc. are major entities operating in this industry.
Manufacturers are forming partnerships with other companies, academic institutions, and research organizations to increase their inotropic agents market share. They are also focused on accelerating the development of new products, improving their distribution channels, and gaining access to new markets.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 1.9 Bn |
|
Market Forecast Value in 2031 |
More than US$ 5.1 Bn |
|
Growth Rate (CAGR) |
11.4% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 1.9 Bn in 2022
It is projected to reach more than US$ 5.1 Bn by the end of 2031
It is anticipated to be 11.4% from 2023 to 2031
Rise in incidence of heart failure and increase in awareness about heart failure and its treatment options
North America is projected to account for major share from 2023 to 2031
Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH., AstraZeneca, Johnson & Johnson, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, and Cipla Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inotropic Agents Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Inotropic Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Insights on Short-term Treatments For Acute Cardiac Care
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Impact Analysis
6. Global Inotropic Agents Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Positive Inotropic Agents
6.3.2. Negative Inotropic Agents
6.4. Market Attractiveness Analysis, by Type
7. Global Inotropic Agents Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Heart Attack
7.3.2. Heart Failure and Cardiogenic Shock
7.3.3. Angina
7.3.4. Arrhythmia
7.3.5. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Inotropic Agents Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Inotropic Agents Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Inotropic Agents Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Positive Inotropic Agents
10.2.2. Negative Inotropic Agents
10.3. Market Value Forecast, by Indication, 2017–2031
10.3.1. Heart Attack
10.3.2. Heart Failure and Cardiogenic Shock
10.3.3. Angina
10.3.4. Arrhythmia
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Parenteral
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Indication
10.6.3. By Route of Administration
10.6.4. By Country
11. Europe Inotropic Agents Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Positive Inotropic Agents
11.2.2. Negative Inotropic Agents
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Heart Attack
11.3.2. Heart Failure and Cardiogenic Shock
11.3.3. Angina
11.3.4. Arrhythmia
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Indication
11.6.3. By Route of Administration
11.6.4. By Country/Sub-region
12. Asia Pacific Inotropic Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Positive Inotropic Agents
12.2.2. Negative Inotropic Agents
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. Heart Attack
12.3.2. Heart Failure and Cardiogenic Shock
12.3.3. Angina
12.3.4. Arrhythmia
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Indication
12.6.3. By Route of Administration
12.6.4. By Country/Sub-region
13. Latin America Inotropic Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Positive Inotropic Agents
13.2.2. Negative Inotropic Agents
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Heart Attack
13.3.2. Heart Failure and Cardiogenic Shock
13.3.3. Angina
13.3.4. Arrhythmia
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Indication
13.6.3. By Route of Administration
13.6.4. By Country/Sub-region
14. Middle East & Africa Inotropic Agents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Positive Inotropic Agents
14.2.2. Negative Inotropic Agents
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. Heart Attack
14.3.2. Heart Failure and Cardiogenic Shock
14.3.3. Angina
14.3.4. Arrhythmia
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Indication
14.6.3. By Route of Administration
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview
15.3.1.2. Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GSK plc
15.3.2.1. Company Overview
15.3.2.2. Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Mylan N.V.
15.3.4.1. Company Overview
15.3.4.2. Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Boehringer Ingelheim International GmbH
15.3.5.1. Company Overview
15.3.5.2. Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AstraZeneca
15.3.6.1. Company Overview
15.3.6.2. Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Johnson & Johnson
15.3.7.1. Company Overview
15.3.7.2. Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bayer AG
15.3.8.1. Company Overview
15.3.8.2. Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Merck & Co., Inc.
15.3.9.1. Company Overview
15.3.9.2. Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bristol-Myers Squibb Company
15.3.10.1. Company Overview
15.3.10.2. Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Cipla Inc.
15.3.11.1. Company Overview
15.3.11.2. Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Other Prominent Players
15.3.12.1. Company Overview
15.3.12.2. Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
List of Tables
Table 01: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Inotropic Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 13: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
List of Figures
Figure 01: Global Inotropic Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Inotropic Agents Market Revenue (US$ Mn), by Type, 2022
Figure 03: Global Inotropic Agents Market Value Share, by Type, 2022
Figure 04: Global Inotropic Agents Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Inotropic Agents Market Value Share, by Indication, 2022
Figure 06: Global Inotropic Agents Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 07: Global Inotropic Agents Market Value Share, by Route of Administration, 2022
Figure 08: Global Inotropic Agents Market Value Share, by Region, 2022
Figure 09: Global Inotropic Agents Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 11: Global Inotropic Agents Market Attractiveness Analysis, by Type, 2022-2031
Figure 12: Global Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 13: Global Inotropic Agents Market Attractiveness Analysis, by Indication, 2022-2031
Figure 14: Global Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 15: Global Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 16: Global Inotropic Agents Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Inotropic Agents Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Inotropic Agents Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Inotropic Agents Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 22: North America Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 23: North America Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 24: North America Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031
Figure 25: North America Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26:North America Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 27: Europe Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 31: Europe Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 32: Europe Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 33: Europe Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031
Figure 34: Europe Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 36: Asia Pacific Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 40: Asia Pacific Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 41: Asia Pacific Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 42: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031
Figure 43: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 45: Latin America Inotropic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 49: Latin America Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 50: Latin America Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 51: Latin America Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031
Figure 52: Latin America Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 54: Middle East & Africa Inotropic Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Type, 2022 and 2031
Figure 58: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Indication, 2022 and 2031
Figure 59: Middle East & Africa Inotropic Agents Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 60: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Type, 2023–2031
Figure 61: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Indication, 2023–2031
Figure 62: Middle East & Africa Inotropic Agents Market Attractiveness Analysis, by Route of Administration, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Inotropic Agents Market
*86 figures and 60 tables includes